Showing posts with label Drug. Show all posts
Showing posts with label Drug. Show all posts

Saturday, September 28, 2013

New Inhaler Drug Approved By FDA For Chronic COPD








The U.S. Food and Drug Administration has just announced the approval of a form of new long-term treatment for patients suffering from chronic obstructive pulmonary disease (COPD). The new treatment is an inhaler drug called Breo Ellipta (fluticasone furoate and vilanterol inhalation powder). It is also approved for the treatment of exacerbations in COPD patients.




COPD is a form of lung disease that progressively gets worse, it is characterized by the occurrence of chronic bronchitis oremphysema (a pair of co-existing diseases that narrow the airways). Symptoms include shortness of breath, chronic cough, chest tightness and excessive phlegm. COPD is one of the leading causes of death worldwide. The National Heart, Lung, and Blood Institute reported that it is the third leading cause of death in the U.S.




According to a previous study published in PLoS Med, by 2030 COPD is predicted to become the fourth leading cause of death. 




Current and former long-term smokers are at the highest risk of developing COPD. A study published in the journal Thorax revealed that smokers have a 25% chance of developing COPD.




Management strategies of the disease include: quitting smoking (among smokers), vaccination and drug therapies (usually involving the use of inhalers). Two years ago the FDA approved a similar form of treatment to Breo Ellipta called Arcapta Neohaler (indacaterol inhalation powder)for the long term, once-daily maintenance bronchodilator treatment of airflow obstruction in people with COPD.




According to Curtis Rosebraugh, M.D., M.P.H., director, Office of Drug Evaluation II, Center for Drug Evaluation and Research, FDA:







“COPD is a serious disease that makes breathing difficult. The availability of new long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD.”










The new inhaler, developed by GlaxoSmithKline, works by reducing inflammation in the lungs as well as relaxing the muscles around the airways, which improves airflow and prevents wheezing and breathlessness.




Breo Ellipta is a combination of two different drugs: fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta2-adrenergic agonist (LABA).




Researchers evaluated the effectiveness of the inhaler in 7,700 people who were diagnosed with COPD. 




The results of the study indicated that, compared to placebo, Breo Ellipta was very effective at improving lung function and reducing exacerbations. 




Breo Ellipta is not approved for the treatment of asthma. In fact, as a LABA, the drug’s box label will include a warning that it can increase the risk of asthma-related death. In addition, the medication is not recommended for people under the age of 18 and should not be used as a rescue therapy to treat sudden breathing complications. 




Side effects linked to Breo Ellipta therapy include:

Increased risk of pneumonia

Bone fractures

Headache

Inflammation of the nasal passage

Thrush

Upper respiratory tract infection

The future of COPD management




Recently, researchers from the Boston University School of Medicine identified a genetic signature for COPD from harvested airway cells. The finding has huge potential for new treatment options and provides a novel way to study the condition. One of the senior authors of the study, Avrum Spira, MD, MSc, Alexander said: “Our data shows that there are consistent gene-expression changes that occur in both airway and lung tissue cells in individuals with COPD.”




She added:







“Part of the COPD ‘signature’ reverses with therapy, suggesting that examining airway cells might be a minimally invasive tool for monitoring the disease and evaluating the response to therapy more quickly in order to determine the best course of treatment for each individual patient.”










Another study, published in the April 2013 issue of The Journal of Nuclear Medicine, revealed that earlier diagnosis of COPD could be achieved using a novel technique known as in vivo ventilation/perfusion (V/Q) 

imaging.







by






Wednesday, September 25, 2013

FDA Probes Allergy Drug and Suicides - Associated Press

By MATTHEW PERRONE,AP


WASHINGTON (March 28) – The Food and Drug Administration said Thursday it is investigating a possible link between Merck’s best-selling Singulair and suicide.


FDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.


Merck has updated the drug’s labeling four times in the past year to include information on a range of reported side effects: tremors, anxiousness, depression and suicidal behavior.


FDA said it asked the Whitehouse, N.J.-based company to dig deeper into its data on Singulair for evidence of possible links to suicide. The agency said it has not established a “causal relationship” between Merck’s drug and suicidal behavior. An agency spokeswoman said the review was prompted by three to four suicide reports it received since last October.


It could take up to nine months before agency scientists can draw any conclusions, FDA said in a posting to its Web site.


The agency recently began notifying the public earlier about possible safety issues. The policy change came after the FDA was criticized for acting too slowly on information about the risks of Merck’s painkiller Vioxx and, GlaxoSmithKline plc’s diabetes pill Avandia.


Merck officials stressed that the FDA’s inquiry is based on reports, not clinical studies – which are the standard tool for evaluating drug safety. The company said none of the 11,000 patients enrolled in 40 Singulair trials has committed suicide.


“We have no indication that anything about the mechanism of Singulair is consistent with these events,” said George Philip, director of research and product development. “But because suicide is a life-threatening event we thought it was important to provide this information in the product label.”


Merck said it recently added reports of suicide to Singulair’s label, which already listed suicidal thinking and behavior as reported side effects.


In clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.


With sales of $ 4.3 billion last year, Singulair is used by millions of patients in the U.S, according to Merck. First approved in 1998, it’s part of a class of asthma and allergy drugs that includes AstraZeneca’s Accolate and Critical Therapeutics’s Zyflo.


FDA said it is also reviewing reports of side effects with those drugs. Their labeling does not contain language about suicide.


“Patients should not stop taking Singulair before talking to their doctor,” FDA said in its statement, adding that doctors should monitor patients for suicidal behavior and mood changes.


Shares of Merck & Co. Inc. rose 8 cents to close at $ 44.78.